A simple, accurate and precise densitometry method for the simultaneous estimation melatonin (MEL) and zolpidem (ZOL) in pharmaceutical dosage forms has been developed and validated. Separation of drugs was carried out using toluene: n-butanol: glacial acetic acid: water (1:4:2:2v/v/v/v) as mobile phase on precoated Silica Gel 60F plates. The densitometry evaluation of spot was carried out at 254 nm. The R 254 f value for MEL and ZOL were found to be 0.87±0.01 and 0.59±0.01 respectively. The method was validated with respect to linearity, accuracy, precision and robustness as per the International Conference on Harmonization (ICH) guidelines. The drug response with respect to peak area was linear over the concentration range 150-900 ng/spot and 250-1500 ng/spot for MEL and ZOL respectively, limit of detection and limit of quantitation were found to be 14.96 ng/spot and 45.60 ng/spot for MEL and 19.53 ng/spot and 59.24 ng/spot for ZOL. The percentage recovery of MEL and ZOL were found be 99.04-99.35% and 98.11-98.77% respectively. The % RSD values for (intra-day RSD 0.26-0.56% and inter-day RSD 0. 36-0.78 %for MEL and intraday RSD 0.18-0.31% and inter day 0.23-0.31% for ZOL). It was observed that the proposed HPTLC method could be used for efcient analysis and monitoring of the MEL and ZOL in combined tablet dosage forms.
INTRODUCTION

Melatonin (MEL) is chemically, N-[2-(5-
. It is used for short-term treatment of insomnia, as well as some brain disorders. It is short-acting non benzodiazepine hypnotic of the imidazo pyridine class that potentiates gamma-amino butyric acid (GABA), an inhibitory neurotransmitter.
1A. Melatonin
1B. Zolpidem
Fig.1: Chemical structure of (A) Melatonin and (B) Zolpidem
Literature survey reported that many analytical methods [3] [4] for quantitation of MEL by RP-HPLC and by radio- 5 immunoassay in individual and in combination with other drugs. Several methods have been described for 6-7, the determination of ZOL by UV spectrophotometry 8-9, stability indicating HPLC bulk drugs and human [10] [11] plasma reported for the simultaneous estimation of
MATERIALS AND METHODS Instrumentation
The samples were spotted in the form of bands of 6 mm using a Camag 100 µl microliter syringe on silica gel precoated aluminium plate 60 GF , (20 cm X 10 cm X 254 250 µm; E. Merck) The plates were prewashed with methanol and activated at 110º C for 5min (prior to chromatography). Space between two bands was maintained as 6 mm. A constant application rate of 100nl/s was employed Camag Linomet 5 Automatic TLC sample applicator. The slit dimension was kept at 5 mm X 0.45 mm and 10mm/s scanning speed was employed. The monochromator bandwidth was set at 20 nm, each track was scanned trice and the baseline correction was used. Linear ascending development was carried out in a 20 cm X 10 cm twin through glass chamber saturated with the mobile phase. The optimized chamber saturation time for mobile phase was 30 min at room temperature (25ºC±2) at relative humidity of 60±5%. The length of chromatogram run was 8 cm. Subsequent to the development, HPTLC plates were dried in current of air with the help of an air dryer in a wooden chamber with adequate ventilation. Densitometry scanning was performed on a Camag HPTLC III scanner in the reectance absorbance mode at 254 nm and operated by WIN CATS software (V 3.1.0, Camag). The source of radiation utilized was deuterium lamp emitting continuous UV spectrum between 190 and 400 nm.
Reagents and chemicals
Melatonin and Zolpidem standard substance (sample of MEL, % purity 99.43% and ZOL, % purity 99.62%) were provided as a gift sample by Reltfen Pharmaceutical, Pondicherry. These samples were used without further purication. The tablet formulation (Brand name: Zolcalm-5; label claim containing MEL 3mg and 5mg) was used for the analysis. All chemicals and reagents of analytical grade were purchased from Merck chemicals Ltd., Mumbai, India.
Preparation of standard solution MEL and ZOL stock solution was prepared in methanol and sonicated for 10 min to obtain standard stock solution concentrations of 1000µg/ml. From this 1.5ml of MEL and 2.5 ml of ZOL were transferred to 10 ml ask and diluted to volume with methanol to obtain the nal concentration contains 150 µg/ml for MEL and 250µg/ml for ZOL.
Preparation of sample solution
To d e t e r m i n e t h e c o n t e n t o f M E L a n d Z O L simultaneously in a conventional tablet (Zolcalm-5, Label claim 3 mg MEL and 5 mg ZOL per tablet), twenty tablets were accurately weighed, and average weight determined and ground to ne powder. A quantity of powder equivalent to 3 mg of MEL, 5 mg of ZOL was transferred into a 10 ml volumetric ask containing 6 ml of methanol, sonicated for 30 min and diluted to mark with methanol. The resulting solution was ltered using Whatman paper No.41. So, the solution was further dilute with found to contain150 µg/ml and 250µg/ml for MEL and ZOL.
Analysis of tablet formulation
The resultant solution was found to be contain 150 µg/ml and 250 µg/ml for MEL and ZOL and two µl of this solution was applied on TLC plate and developed in mobile phase of toluene: n-butanol: glacial acetic acid: water (1:4:2:2 v/v/v/v) . The analysis was repeated for three times.
Development and Validation of HPTLC method
Validation of the optimized HPTLC method was carried out with respect to the following parameters according to ICH norms.
Linearity and range
From the standard stock solution (150 µg/ml of MEL and 250µg/ml of ZOL), 1-6 µl were spotted on the TLC plate to obtain the concentration 150-900 ng/spot for MEL and 250-1500 ng/spot for ZOL. The plate was then developed using the previously described mobile phase and the peak areas were plotted against the corresponding concentration to obtain the calibration curve.
Precision
The precision of the method was determined in terms of intra-day and inter-day variation (%RSD) was assessed by analyzing standard drug solutions within the concentration of calibration range, three times on the same day. Inter-day precision (%RSD) was assumed by analyzing standard solutions within the calibration range on three consecutive days.
Accuracy (%Recovery)
Accuracy of the method was carried out by applying the proposed method to the test sample (MEL and ZOL combination tablet). To which a known amount of MEL and ZOL sample corresponding to 80%, 100% and 120% of label claim (Standard addition method) and analyzed by running chromatogram in an optimized mobile phase. This was done to check for the recovery of the drug at different levels in the formulation.
Limit of detection and limit of quantication
The detection limit of assay is the lowest concentration that can be detected. The quantitation limit is the lowest concentration that can be quantied with acceptable precision. The quantitation limit is the lowest level of analyte that can be reported. The ICH guidelines suggest three different methods for determining the detection and quantitation limits. The visual determinations, signal-to-noise ratio determination and standard deviation and slope method. The signal-to-noise ratio method low levels of the analyte to a blank or background sample, measured signals from samples with known low concentrations of analyte with those of blank samples and subsequently establishing the minimum concentration at which analyte can be reliably detected. LOD is calculated by, LOD = 3 * SD/slope ofduring determination of MEL and ZOL. Robustness was determined by changing in mobile phase, development distance and saturation time.
Specicity
The specicity of the method was determined by analyzing standard drug and test samples. The identities of the spots for MEL and ZOL were conrmed by comparing the R and spectra of the spots with that of the f standard. Peak purity of MEL and ZOL was assessed by comparing the spectra at three different point leads the peak start(S), peak apex (M), and peak end (E) positions of the spot. The wavelength 254 nm was selected for densitometry scanning. 
RESULT AND DISCUSSION
Analysis of tablet formulation
Two µL of sample solution was applied to an HPTLC plate to give nal amount of 300 ng/spot and 500ng/spot MEL and ZOL. After the chromatographic development, peak areas of the bands were measured and amount of each drug was estimated from the respective calibration plots. The procedure was repeated three times. The average assays (n=3) were 98.86 ± 0.13 and 98.29 ± 0.54 for MEL and ZOL respectively. Experimental results for the amount of MEL and ZOL, the percentage of label claims were in good agreement with the label claims and thereby suggesting that there is no interference from any of the excipients which are normally present in tablets and the results are tabulated in Table 1 . 
Linearity
Linear regression data for the calibration plots revealed g o o d l i n e a r r e l a t i o n s h i p s b e t w e e n a r e a a n d concentration over the ranges 150-900 ng /spot for MEL and 250-1500 ng /spot for ZOL. The linear regression equations were Y=2.0756X+113.67 for MEL and Y=2.0624X+358.01 for ZOL respectively. The calibration 2 plots were with regression (r ) being 0.9809 and 0.9929 for MEL and ZOL respectively in Table 2 (Fig 3 and 4) . 
Precision
Results from determination of intraday and interday precision, were expressed as SD and relative standard deviation (RSD %). The precision of the proposed method were < 2%, conrming that the method was sufciently precise in Table 3 & 4. 
Recovery
The accuracy of the method was obtained on the basis of recovery studies performed by standard addition method with 80,100 and120% of the label claim each in triplicate. A known amount of each standard powder was mixed with sample of tablet powder and these were then analyzed as described above. The results from recovery analysis was found to be 100.13-100.25% with RSD 0.21-0.31% for MEL and 99.61-99.89% with RSD 0.24-0.38% for ZOL. Table 5 . 
Robustness of the methods
The relative standard deviation of peak areas was less than 2%. These percent RSD indicates the robustness of the method in Table 6 . 
Specicity
The mobile phase resolved both the drugs very efciently, as shown in Fig 2. The peak purity of MEL and ZOL were assessed by comparing their respective spectra at the peak start, apex, and peak end positions 2 2 of the spot, r = 0.9973 and r = 0.9995. A good correlation was also obtained between the standard and sample spectra of MEL and ZOL respectively. Also excipients from formulation were not interfering with the assay. Also excipients from formulation were not interfering with the assay.
CONCLUSION
The developed HPTLC technique is simple, accurate, precise and reproducible for simultaneous determination of melatonin and zolpidem in pharmaceutical dosage forms. In this method reduces cost per analysis and analysis time, suitable for routine analysis of pharmaceutical formulations in quality-control laboratories. The major advantage of HPTLC is that several samples can be run simultaneously using a minimum sample preparation and small quantity of mobile phase.
